cartesiantherapeutics.com
Cartesian Initiates CAR-T Clinical Trial in Myasthenia Gravis
First CAR-T to enter clinical development for an autoimmune disease Descartes-08 engineered to have a defined, predictable half-life, enabling repeat dosing to maximize potential for potency while minimizing risk of toxicity Gaithersburg, MD, November 5, 2019 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company developing cell and gene therapies for cancer and